Dylan Beynon, founder of Mindbloom, shares the deeply personal story behind building the first at-home ketamine therapy platform. After losing his mother and sister to severe mental illness, Dylan became determined to bring psychedelic medicine into mainstream healthcare. He explains the neuroscience of how ketamine creates neuroplasticity—allowing the brain to rewire itself—and why these treatments are showing 10x better outcomes than SSRIs. From navigating FDA breakthrough therapy designations to dismantling decades of stigma from Nixon-era drug policy, Dylan reveals how Mindbloom is democratizing access to treatments that were once only available in $5,000 in-person clinics.

Hosted on Acast. See acast.com/privacy for more information.